A 12-month trial of 0.9 mg/day spermidine in older adults with subjective cognitive decline found higher blood flow in the precuneus and steadier white-matter integrity versus placebo. But this exploratory MRI analysis of 75 SmartAge participants showed no changes in brain volume, cortical thickness, or white-matter hyperintensities. Crucially, the imaging changes weren't linked to memory, and the parent trial found no memory benefit. Here's what the signal might mean, what it doesn't, and the practical details on dose and food sources.
This page is available in